HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

BACKGROUND: In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry (IHC) 3+/fluorescence in situ hybridization-positive] gastric/g...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, Eric, Bang, Yung-Jue, Feng-yi, Feng, Xu, Jian M., Lee, Keun-Wook, Jiao, Shun-Chang, Chong, Jorge León, López-Sanchez, Roberto I., Price, Timothy, Gladkov, Oleg, Stoss, Oliver, Hill, Julie, Ng, Vivian, Lehle, Michaela, Thomas, Marlene, Kiermaier, Astrid, Rüschoff, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511072/
https://www.ncbi.nlm.nih.gov/pubmed/25038874
http://dx.doi.org/10.1007/s10120-014-0402-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511072/
https://www.ncbi.nlm.nih.gov/pubmed/25038874
http://dx.doi.org/10.1007/s10120-014-0402-y

Ejemplares similares